Introduction
============

Sumatriptan is a frequently applied anti-migraine treatment, yet ≈20-30% migraineurs are nonresponders. TRPV1 channels on trigeminal nerve endings release CGRP during migraine attacks, while, supposedly, stimulation of the presynaptic 5-HT(1B)/1D receptor by sumatriptan inhibits this release. Capsaicin (CAP) stimulates TRPV1 channels, causing CGRP-dependent vasodilatation, whereas electrical stimulation (ES) induces vasodilation without direct TRPV1 activation.

Aim
===

To assess a possible biomarker for the efficacy of sumatriptan.

Methods
=======

We investigated the effect of sumatriptan on the rise of dermal blood flow (DBF) of the forehead skin (innervated by the trigeminal nerve) by CAP application (0.6 mg/ml) and ES (0.2-1.0 mA) before and after subcutaneous placebo and sumatriptan in a randomized, double-blind, placebo controlled cross-over study, including healthy male (n=11, age±SD: 29±8 yrs) and female (n=11, 32±7 yrs) subjects.

Results
=======

DBF responses to CAP (mean±SEM: 313±16 A.U.) were significantly attenuated after sumatriptan (mean decrease DBF: 82±18 A.U., p \< 0.001) but not after placebo (mean decrease DBF: 21±12 A.U., p = 0.1026), whereas DBF responses to ES were not affected by sumatriptan or placebo. Sumatriptan, but not placebo, increased blood pressure by 6±2/11±2 mmHg, p \< 0.001. In 23% of the subjects, sumatriptan did not attenuate the DBF response.

Conclusions
===========

Sumatriptan may inhibit the release of CGRP via the stimulation of the presynaptic 5-HT(1B)/1D receptor and/or by a direct effect on TRPV1 channels. ES appears to be a nonspecific stimulus, most likely releasing other neuropeptides besides CGRP. Future studies should indicate whether nonresponse in our model correlates with clinical nonresponse to sumatriptan.
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